NIH team touts experimental Epstein-Barr virus vaccine; Madison Vaccines pairs its prostate cancer jab with Keytruda;

> A nanoparticle-based experimental vaccine, developed by a team from the National Institute of Allergy and Infectious Diseases and its collaborators, was shown to induce antibodies against Epstein-Barr virus in mice and primates. Release

> Madison Vaccines initiated a combination trial of its lead prostate cancer vaccine candidate paired with Merck's ($MRK) checkpoint inhibitor Keytruda. Release

> Emergent BioSolutions ($EBS) received a $44 million contract option for the supply of its Vigiv--which treats complications due to smallpox vaccination--to the national stockpile. Release

Suggested Articles

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.

Univercells's new CDMO, Exothera, is hoping to play a role in helping drugmakers scale up manufacturing for a possible COVID-19 vaccine.